正常人或患者外周血、骨髓单个核细胞/淋巴细胞中定期加入γ-干扰素(IFN-γ)、白细胞介素-1(IL-1)、白细胞介素-2(IL-2)、抗CD3抗体(CD3mAb)经2～4周的诱导可获得大量的新型肿瘤杀伤细胞——细胞因子诱导的杀伤细胞(cytokine-induced killer,CIK),增殖旺盛及肿瘤杀伤活性高,包含大量CD3~+CD56~+细胞。有关基础及临床研究证明,CIK细胞较细胞毒性T淋巴细胞(CTL)、淋巴细胞因子活化的杀伤细胞(lymphokine-activated killer,LAK)、肿瘤细胞浸润的淋巴细胞(tumer infiltrating-lym-phocyte,TIL)更适用于肿瘤的生物治疗。本文就CIK细胞的来源与生物学特征、对肿瘤细胞的杀伤及临床应用进行综述。 Normal human or patients with peripheral blood, bone marrow mononuclear cells / lymphocytes were regularly added interferon (IFN-), interleukin-1 (IL-1), interleukin-2 (IL-2), anti CD3 antibody (CD3 mAb) can induce a large number of new cytokine-induced killer (CIK) cells after 2 to 4 weeks of induction, with strong proliferation and high tumor-killing activity, including a large number of CD3 + CD56 ~ + cells. The basic and clinical studies have shown that CIK cells are more effective than cytotoxic T lymphocytes (CTLs), lymphokine-activated killers (LAKs), tumer infiltrating-lym-phocytes (TILs) ) Is more suitable for biological treatment of tumors. In this paper, the source and biological characteristics of CIK cells, the killing of tumor cells and clinical application are reviewed.